Literature DB >> 24900294

Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.

Timothy I Richardson1, Christian A Clarke1, Kuo-Long Yu1, Ying K Yee1, Thomas J Bleisch1, Jose E Lopez1, Scott A Jones1, Norman E Hughes1, Brian S Muehl1, Charles W Lugar1, Terry L Moore1, Pamela K Shetler1, Richard W Zink1, John J Osborne1, Chahrzad Montrose-Rafizadeh1, Nita Patel1, Andrew G Geiser1, Rachelle J Sells Galvin1, Jeffrey A Dodge1.   

Abstract

We report the synthesis and characterization of novel 3-aryl indoles as potent and efficacious progesterone receptor (PR) antagonists with potential for the treatment of uterine fibroids. These compounds demonstrated excellent selectivity over other steroid nuclear hormone receptors such as the mineralocorticoid receptor (MR). They were prepared from 2-bromo-6-nitro indole in four to six steps using a Suzuki cross-coupling as the key step. Compound 8f was orally active in the complement 3 model of progesterone antagonism in the rat uterus and demonstrated partial antagonism in the McPhail model of progesterone activity.

Entities:  

Keywords:  NR3C3; Progesterone; Suzuki cross-coupling reaction; progesterone receptor; progesterone receptor antagonist; uterine fibroids

Year:  2010        PMID: 24900294      PMCID: PMC4017981          DOI: 10.1021/ml100220b

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

1.  Biomedicine. Defining the "S" in SERMs.

Authors:  Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

2.  In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.

Authors:  Barbara J Attardi; Janet Burgenson; Sheri A Hild; Jerry R Reel
Journal:  J Steroid Biochem Mol Biol       Date:  2004-03       Impact factor: 4.292

3.  The assay of progestin.

Authors:  M K McPhail
Journal:  J Physiol       Date:  1934-12-31       Impact factor: 5.182

4.  Low molecular weight indole fragments as IMPDH inhibitors.

Authors:  Rebekah E Beevers; George M Buckley; Natasha Davies; Joanne L Fraser; Francis C Galvin; Duncan R Hannah; Alan F Haughan; Kerry Jenkins; Stephen R Mack; William R Pitt; Andrew J Ratcliffe; Marianna D Richard; Verity Sabin; Andrew Sharpe; Sophie C Williams
Journal:  Bioorg Med Chem Lett       Date:  2006-02-17       Impact factor: 2.823

5.  Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety.

Authors:  Timothy I Richardson; Scott A Frank; Minmin Wang; Christian A Clarke; Scott A Jones; Bai-Ping Ying; Dan T Kohlman; Owen B Wallace; Timothy A Shepherd; Robert D Dally; Alan D Palkowitz; Andrew G Geiser; Henry U Bryant; Judith W Henck; Ilene R Cohen; Daniel G Rudmann; Denis J McCann; David E Coutant; Samuel W Oldham; Conrad W Hummel; Kin C Fong; Ronald Hinklin; George Lewis; Hongqi Tian; Jeffrey A Dodge
Journal:  Bioorg Med Chem Lett       Date:  2007-04-24       Impact factor: 2.823

6.  A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri.

Authors:  A J Friedman; R L Barbieri; P M Doubilet; C Fine; I Schiff
Journal:  Fertil Steril       Date:  1988-03       Impact factor: 7.329

7.  Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone.

Authors:  S G Lundeen; Z Zhang; Y Zhu; J M Carver; R C Winneker
Journal:  J Steroid Biochem Mol Biol       Date:  2001-08       Impact factor: 4.292

8.  Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development.

Authors:  Mark D Aupperlee; Kyle T Smith; Anastasia Kariagina; Sandra Z Haslam
Journal:  Endocrinology       Date:  2005-05-05       Impact factor: 4.736

Review 9.  A benefit-risk assessment of medical treatment for uterine leiomyomas.

Authors:  Vincenzo De Leo; Giuseppe Morgante; Antonio La Marca; Maria Concetta Musacchio; Massimo Sorace; Chiara Cavicchioli; Felice Petraglia
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

10.  Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study.

Authors:  L Fedele; F Parazzini; L Luchini; R Mezzopane; L Tozzi; L Villa
Journal:  Hum Reprod       Date:  1995-07       Impact factor: 6.918

View more
  5 in total

1.  Transition-Metal-Free C3 Arylation of Indoles with Aryl Halides.

Authors:  Ji Chen; Jimmy Wu
Journal:  Angew Chem Int Ed Engl       Date:  2017-03-03       Impact factor: 15.336

2.  Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.

Authors:  Yuko Nishiyama; Shuichi Mori; Makoto Makishima; Shinya Fujii; Hiroyuki Kagechika; Yuichi Hashimoto; Minoru Ishikawa
Journal:  ACS Med Chem Lett       Date:  2018-06-23       Impact factor: 4.345

3.  Treatment for Uterine Fibroids: Searching for Effective Drug Therapies.

Authors:  Darlene K Taylor; Phyllis C Leppert
Journal:  Drug Discov Today Ther Strateg       Date:  2012

4.  Synthesis of Tridentate [1,2,4] Triazinyl-Pyridin-2-yl Indole Lewis Basic Complexants via Pd-Catalyzed Suzuki-Miyaura Cross-Coupling.

Authors:  Zachary Z Gulledge; Mariah L Tedder; Kyle R Lyons; Jesse D Carrick
Journal:  ACS Omega       Date:  2019-10-29

5.  StackPR is a new computational approach for large-scale identification of progesterone receptor antagonists using the stacking strategy.

Authors:  Nalini Schaduangrat; Nuttapat Anuwongcharoen; Mohammad Ali Moni; Pietro Lio'; Phasit Charoenkwan; Watshara Shoombuatong
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.